Abstract 379P
Background
About 10% cancers are due to cancer susceptibility genes. Testing of high risk patients according to NCCN guidelines is important for detection of hereditary cases and at-risk relatives for secondary prevention of cancer. The exact burden of germline mutations in Indian population is not known because of lack of education and unaffordability. We undertook this study for detection of hereditary cancer cases from Western India.
Methods
All patients who underwent testing from June 2015 to June 2019 for extended germline mutation panel of 96 genes using next generation sequencing (NGS) on Illumina platform were selected. Clinical data was analysed and correlated with the results.
Results
Out of total 290 patients counselled, 84 (28.9%) underwent genetic testing. Mutations were found in 63 % (53/84) patients whose median age was 44 years. 24.5% (13/53) had no positive family history of cancer. Most common malignancies were breast, 31; of which 15 were triple negative breast cancers, followed by ovary, 13 and colon, 4 cases. BRCA1/BRCA2 mutations were seen in 66% (35/53), MSH2 in 3 and MLH1 and RAD51D mutation in 2 patients each. 38 mutations were pathogenic, 4 likely pathogenic and 11 were Variant of Unknown Significance (VUS). Three novel BRCA1 mutations (c.1039delC, c.42_44dupGCT, c.68-5_77del) and one novel BRCA2 mutation (c.7342A>T) was identified. A rare TP53 mutation (c.(-29 + 1_-28-1)_(672 + 1_673-1)dup) was also identified in one patient, who had three metachronous malignancies.
Conclusions
Hereditary breast and ovarian cancer syndrome due to BRCA1/2 mutations was commonest in our study followed by Lynch syndrome due to MSH2 mutation. 20% VUS, 4 novel and 1 rare mutation were identified. Negative family history does not rule out hereditary predisposition. The knowledge shared would assist in further genetic testing and enable detection of more hereditary cancer cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract